Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionSchroder Investment Management Group
Latest Disclosed Ownership66,662 shares
Latest Disclosed Value $ 22,056,457
Schroder Investment Management Group reports 2.04% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 14, 2026 - Schroder Investment Management Group filed a 13F-HR form disclosing ownership of 66,662 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $19,045,333 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 68,049 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -2.04% during the quarter. The current value of the position is $17,365,451 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 66,662 -1,387 -2.04 22,056 -18.41 0.0036
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 68,049 57,231 529.03 27,032 458.51 0.0205
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,818 2,238 26.08 4,841 73.04 0.0038
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,580 -19,203 -69.12 2,798 -62.50 0.0024
2025-05-13 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,783 4,553 19.60 7,459 36.05 0.0075
2025-02-12 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,230 -24,112 -50.93 5,483 -57.88 0.0053
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,342 -9,382 -16.54 13,015 -5.58 0.0133
2024-08-12 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 56,724 -32,178 -36.19 13,784 3.74 0.0152
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 88,902 44,427 99.89 13,286 56.09 0.0156
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,475 36,820 480.99 8,513 528.19 0.0110
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,655 -548 -6.68 1,356 -13.03 0.0020
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,203 -661 -7.46 1,558 -12.23 0.0022
2023-05-11 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,864 384 4.53 1,776 -11.91 0.0026
2023-02-10 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,480 -598 -6.59 2,015 10.90 0.0032
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,078 -1,745 -16.12 1,817 15.37 0.0030
2022-08-11 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,823 891 8.97 1,575 -4.02 0.0024
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,932 4,221 73.91 1,641 69.52 0.0022
2022-02-14 2021-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 5,711 758 15.30 968 3.53 0.0013
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 4,953 297 6.38 935 18.50 0.0014
2021-08-13 2021-06-30 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 4,656 911 24.33 789 49.15 0.0010
2021-05-28 2021-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 3,745 0 0.00 529 0.0007
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 3,745 0 529 0.0007
2021-02-24 2020-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 3,745 0 0.00 0 -100.00 0.0007
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 3,745 0 0 0.0007
2020-11-13 2020-09-30 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 3,745 206 5.82 508 -3.05 0.0008
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 3,539 1,534 76.51 524 132.89 0.0010
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 2,005 2,005 225 0.0005
2018-05-11 2018-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 0 -3,216 -100.00 0 -100.00
2018-02-09 2017-12-31 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 3,216 3,216 409 0.0007
2017-11-09 2017-09-30 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 0 -22,913 -100.00 0 -100.00
2017-08-10 2017-06-30 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 22,913 0 0.00 1,811 54.26 0.0033
2017-05-18 2017-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 22,913 9,793 74.64 1,174 139.10 0.0021
2017-05-10 2017-03-31 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 22,913 9,793 1,174 2,110.2578
2017-02-10 2016-12-31 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 13,120 -5,472 -29.43 491 -61.03 0.0009
2016-11-09 2016-09-30 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 18,592 0 0.00 1,260 22.09 0.0024
2016-08-08 2016-06-30 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 18,592 13,042 234.99 1,032 214.63 0.0021
2016-05-10 2016-03-31 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 5,550 0 0.00 328 -37.16 0.0007
2016-02-10 2015-12-31 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 5,550 0 0.00 522 17.04 0.0011
2015-11-13 2015-09-30 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 5,550 0 0.00 446 -29.65 0.0009
2015-08-10 2015-06-30 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 5,550 -6,864 -55.29 634 -50.93 0.0012
2015-05-12 2015-03-31 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 12,414 0 0.00 1,292 7.31 0.0025
2015-02-18 2014-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 12,414 -10,768 1,204 0.0024
2015-02-25 2014-12-31 13F/A-2 ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 12,414 -10,768 -46.45 1,204 -33.48 0.0024
2015-02-17 2014-12-31 13F ALNYLAM PHARMACEUTICALS INCORPORATED USD0.01 COM 02043Q107 12,414 -10,768 1,204 1,748.2540
2014-11-13 2014-09-30 13F Alnylam Pharm. Com Stk USD0.01 COM 02043Q107 23,182 374 1.64 1,811 25.69 0.0024
2014-08-13 2014-06-30 13F Alnylam Pharm Com Stk USD0 01 COM 02043Q107 22,808 6,696 41.56 1,441 33.21 0.0018
2014-05-15 2014-03-31 13F Alnylam Pharm. Com Stk USD0.01 COM 02043Q107 16,112 -5,695 -26.12 1,082 -22.90 0.0012
2014-02-14 2013-12-31 13F Alnylam Pharm. Com Stk USD0.01 COM 02043Q107 21,807 -3,863 -15.05 1,402 -14.67 0.0018
2013-12-09 2013-09-30 13F/A-1 Alnylam Pharm. Com Stk USD0.01 COM 02043Q107 1,643,137 1,612,242 105,177 0.0032
2013-12-10 2013-09-30 13F/A-2 Alnylam Pharm. Com Stk USD0.01 COM 02043Q107 25,670 -5,225 -16.91 1,643 71.68 0.0040
2013-11-08 2013-09-30 13F Alnylam Pharm. Com Stk USD0.01 COM 02043Q107 25,670 -5,225 1,643 4.0547
2013-08-12 2013-06-30 13F Alnylam Pharm. Com Stk USD0.01 COM 02043Q107 30,895 30,895 958 0.0025
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.